Increasing efficacy by designing CARs with two specificities

Bi-CAR-T, the next generation of CAR therapy

Bi-CAR-T helps mitigate tumors
Bio4t2 is leveraging its PrismCore and Bio-Engine technologies to generate next-generation Bi-CAR-T for solid tumors. The additional specificity, recognizing two targets, expands the range of tumors that can be addressed and increases the number of patients that may benefit from infusion of Bi-CAR-T. At the same time, Bi-CAR-T helps to mitigate the emergence of tumors that may lose expression of one of the targeted antigens leading to relapse.

Learn more about Bi-CAR-T

View Video
Bio4t2 LinkedIn
Bio4t2TM, PrismCoreTM, Bio-EngineTM and Bio-StrikeTM are trademarks of Bio4t2. Privacy Page »